Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

Taha Sen, Jingwei Li, Brendon L. Neuen, +10

Diabetologia

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Akihiko Koshino, Meir Schechter, Taha Sen, +9

Diabetes Care

Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

Simke W. Waijer, Taha Sen, Clare Arnott, +11

Clinical Journal of the American Society of Nephrology

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>

Taha Sen, Rosalie A. Scholtes, Peter J. Greasley, +12

Diabetes Obesity and Metabolism

Mechanisms of action of the sodium‐glucose cotransporter‐2 ( <scp>SGLT2)</scp> inhibitor canagliflozin on tubular inflammation and damage: A <i>post hoc mediation</i> analysis of the <scp>CANVAS</scp> trial

Taha Sen, Akihiko Koshino, Bruce Neal, +6

Diabetes Obesity and Metabolism

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial

Viktor Rotbain Curovic, Niels Jongs, Marjolein Y. A. M. Kroonen, +8

Diabetes Care

Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes

Taha Sen, Wenjun Ju, Viji Nair, +12

Kidney International